Paper41324846
Therapeutic effects and molecular mechanisms of isorhamnetin against pulmonary diseases.
Jing S and 3 others. Inflammopharmacology, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic effects and molecular mechanisms of isorhamnetin against pulmonary diseases. Papers, record 41324846. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41324846
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Quercetin | Major topic |
| Lung Diseases | Major topic |
| Humans | |
| Animals | |
| COVID-19 Drug Treatment | |
| COVID-19 | |
| Antiviral Agents | |
| Anti-Inflammatory Agents |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 20220303001SF | Department of Science and Technology of Jilin Province | PubMed |
Source PubMed
References97
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34940580 | Metabolite and Bioactive Compounds Profiling of Meteora Sea Buckthorn Berries through High-Resolution NMR Analysis. | Metabolites | 2021 | https://conductscience.org/library/papers/34940580 | PubMed |
| 2 | 33252985 | Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. | Am J Respir Crit Care Med | 2021 | https://conductscience.org/library/papers/33252985 | PubMed |
| 3 | 35306954 | Isorhamnetin alleviates lipopolysaccharide-induced acute lung injury by inhibiting mTOR signaling pathway. | Immunopharmacol Immunotoxicol | 2022 | https://conductscience.org/library/papers/35306954 | PubMed |
| 4 | 35025963 | Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. | PLoS Pathog | 2022 | https://conductscience.org/library/papers/35025963 | PubMed |
| 5 | 35086840 | Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. | Eur Respir J | 2022 | https://conductscience.org/library/papers/35086840 | PubMed |
| 6 | 39073415 | Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/39073415 | PubMed |
| 7 | 32774415 | Network Pharmacology Analysis and Experiments Validation of the Inhibitory Effect of JianPi Fu Recipe on Colorectal Cancer LoVo Cells Metastasis and Growth. | Evid Based Complement Alternat Med | 2020 | https://conductscience.org/library/papers/32774415 | PubMed |
| 8 | 33719855 | Potentiality of Moringa oleifera against SARS-CoV-2: identified by a rational computer aided drug design method. | J Biomol Struct Dyn | 2022 | https://conductscience.org/library/papers/33719855 | PubMed |
| 9 | 33842761 | Analysis of Conformational, Structural, Magnetic, and Electronic Properties Related to Antioxidant Activity: Revisiting Flavan, Anthocyanidin, Flavanone, Flavonol, Isoflavone, Flavone, and Flavan-3-ol. | ACS Omega | 2021 | https://conductscience.org/library/papers/33842761 | PubMed |
| 10 | 37076602 | Therapeutic strategies for COVID-19: progress and lessons learned. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/37076602 | PubMed |
| 11 | 37673198 | Zhisou powder displays therapeutic effect on chronic bronchitis through inhibiting PI3K/Akt/HIF-1α/VEGFA signaling pathway and reprograming metabolic pathway of arachidonic acid. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/37673198 | PubMed |
| 12 | 37752734 | Natural compounds as possible anti-SARS-CoV-2 therapeutic agents: an in-vitro and in-silico study. | Nat Prod Res | 2024 | https://conductscience.org/library/papers/37752734 | PubMed |
| 13 | 33149560 | Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules. | Bioinform Biol Insights | 2020 | https://conductscience.org/library/papers/33149560 | PubMed |
| 14 | 35942366 | Study on the Action Mechanism of the Yifei Jianpi Tongfu Formula in Treatment of Colorectal Cancer Lung Metastasis Based on Network Analysis, Molecular Docking, and Experimental Validation. | Evid Based Complement Alternat Med | 2022 | https://conductscience.org/library/papers/35942366 | PubMed |
| 15 | 31112383 | Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31112383 | PubMed |
| 16 | 31467176 | Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells. | Biosci Rep | 2019 | https://conductscience.org/library/papers/31467176 | PubMed |
| 17 | 35528163 | Network Pharmacological Analysis and Experimental Study of the Antipharyngitis Mechanism of the Chaiqin Qingning Capsule. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35528163 | PubMed |
| 18 | 32914113 | Fat-lowering effects of isorhamnetin are via NHR-49-dependent pathway in Caenorhabditis elegans. | Curr Res Food Sci | 2020 | https://conductscience.org/library/papers/32914113 | PubMed |
| 19 | 37839759 | Isorhamnetin as a novel inhibitor of pneumolysin against Streptococcus pneumoniae infection in vivo/in vitro. | Microb Pathog | 2023 | https://conductscience.org/library/papers/37839759 | PubMed |
| 20 | 33519145 | Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study. | J King Saud Univ Sci | 2021 | https://conductscience.org/library/papers/33519145 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41324846
GET https://conductscience.org/api/papers/v1/41324846/references?page=2